Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma
Teresa C. Longoria, Krishnansu S. Tewari
Expert Opinion on Drug Metabolism & Toxicology (2016) Vol. 12, Iss. 10, pp. 1247-1253
Open Access | Times Cited: 60

Showing 1-25 of 60 citing articles:

Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature
Houssein Safa, Daniel H. Johnson, Van Anh Trinh, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 216
Treatment after progression in the era of immunotherapy
Salem Billan, Orit Kaidar‐Person, Ziv Gil
The Lancet Oncology (2020) Vol. 21, Iss. 10, pp. e463-e476
Closed Access | Times Cited: 156
Advances and Challenges in Targeting TGF-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based Perspective
David Danielpour
Pharmaceuticals (2024) Vol. 17, Iss. 4, pp. 533-533
Open Access | Times Cited: 20
Medical Gas Plasma Jet Technology Targets Murine Melanoma in an Immunogenic Fashion
Sander Bekeschus, Ramona Clemen, Felix Nießner, et al.
Advanced Science (2020) Vol. 7, Iss. 10
Open Access | Times Cited: 105
Pembrolizumab- induced subacute cutaneous lupus erythematosus in a patient with oropharyngeal squamous cell carcinoma: A case report and literature review
Beate Mayer, Pavel Babál, Lucia Krivošíková
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access | Times Cited: 1
Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma
Elena De Mattia, Erika Cecchin, Michela Guardascione, et al.
World Journal of Gastroenterology (2019) Vol. 25, Iss. 29, pp. 3870-3896
Open Access | Times Cited: 75
Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies
Aude Desnoyer, Sophie Broutin, J Delahousse, et al.
European Journal of Cancer (2020) Vol. 128, pp. 119-128
Closed Access | Times Cited: 69
New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness
Isabel Corraliza-Gorjón, Beatriz Somovilla-Crespo, Silvia Santamaría Santamaría, et al.
Frontiers in Immunology (2017) Vol. 8
Open Access | Times Cited: 63
<p>Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data</p>
Pauline du Rusquec, Ombline de Calbiac, Marie Robert, et al.
Cancer Management and Research (2019) Vol. Volume 11, pp. 4297-4312
Open Access | Times Cited: 60
Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges
Xuerun Peng, Zhipeng Zhao, Liwen Liu, et al.
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 2639-2657
Open Access | Times Cited: 28
Immune checkpoint inhibitors in liver transplant: a case series
Mark Rudolph, Shimul A. Shah, Ralph C. Quillin, et al.
Journal of Gastrointestinal Oncology (2023) Vol. 14, Iss. 2, pp. 1141-1148
Open Access | Times Cited: 21
Association of Immunotherapy With Overall Survival in Elderly Patients With Melanoma
Marie Perier‐Muzet, Elodie Gatt, Julien Péron, et al.
JAMA Dermatology (2017) Vol. 154, Iss. 1, pp. 82-82
Open Access | Times Cited: 61
Stable liver graft post anti‐PD1 therapy as a bridge to transplantation in an adolescent with hepatocellular carcinoma
Elise Kang, Mercedes Martínez, Hanna Moisander‐Joyce, et al.
Pediatric Transplantation (2021) Vol. 26, Iss. 3
Open Access | Times Cited: 29
Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models
Sujatha Kumar, Srimoyee Ghosh, Geeta Sharma, et al.
mAbs (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 27
Current challenges of hematologic complications due to immune checkpoint blockade: a comprehensive review
Paola Ghanem, Kristen A. Marrone, Satish Shanbhag, et al.
Annals of Hematology (2021) Vol. 101, Iss. 1, pp. 1-10
Closed Access | Times Cited: 27
Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors
Ting Yan, Yu Lun, Dangang Shangguan, et al.
International Immunopharmacology (2022) Vol. 115, pp. 109638-109638
Open Access | Times Cited: 21
Immune Checkpoint Inhibitors in Melanoma: A Review of Pharmacokinetics and Exposure–Response Relationships
Cyril Leven, Maël Padelli, Jean‐Luc Carré, et al.
Clinical Pharmacokinetics (2019) Vol. 58, Iss. 11, pp. 1393-1405
Open Access | Times Cited: 34
Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition
Abdul Rafeh Naqash, Ebenezer Appah, Li V. Yang, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 30
Cardiovascular Complications of Prostate Cancer Treatment
Michał Wilk, Anna Waśko-Grabowska, Sebastian Szmit
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 26
Advantages of the Combinatorial Molecular Targeted Therapy of Head and Neck Cancer—A Step before Anakoinosis-Based Personalized Treatment
Robert Kleszcz
Cancers (2023) Vol. 15, Iss. 17, pp. 4247-4247
Open Access | Times Cited: 7
Immunogenic cell death induced by low temperature plasma to activate antitumor immunity and enhance therapeutic efficiency
Xiangni Wang, Xiying Wang, J. Liu, et al.
Journal of Physics D Applied Physics (2024) Vol. 57, Iss. 20, pp. 205204-205204
Closed Access | Times Cited: 2
Application of newly developed and validated lc-ms/ms method for pharmacokinetic study of adagrasib and pembrolizumab simultaneously in rat plasma
Kamma Harsha Sri, Panchumarthy Ravisankar, Sathish Kumar Konidala, et al.
Journal of Chromatography B (2024) Vol. 1241, pp. 124171-124171
Closed Access | Times Cited: 2
Pembrolizumab for the treatment of gastric cancer
Suneel D. Kamath, Aparna Kalyan, Al B. Benson
Expert Review of Anticancer Therapy (2018) Vol. 18, Iss. 12, pp. 1177-1187
Closed Access | Times Cited: 22
Mathematical modeling of cancer treatment with radiation and PD-L1 inhibitor
Xiulan Lai, Avner Friedman
Science China Mathematics (2020) Vol. 63, Iss. 3, pp. 465-484
Closed Access | Times Cited: 19
Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?
Kartik Sehgal, Daniel B. Costa, Deepa Rangachari
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top